Physician profile
Joy Tang
NPI 1679006019
$1,357.64
in general payments reported to CMS, 2019-2025
7 companies · $53.45 in 2025
The $53.45 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $99.99 · 2023: $1,204 · 2025: $53.45.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $991 · Education: $267.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $990.96 |
| Education | $266.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $466.95 | 2023 | Pemazyre, Jakafi, Monjuvi |
| Beigene USA, INC. | $259.90 | 2023 | Brukinsa |
| Astellas Pharma US INC | $213.28 | 2022-2023 | Xospata |
| Exelixis INC. | $162.17 | 2023 | Cabometyx |
| Jazz Pharmaceuticals INC. | $110.12 | 2023 | |
| Foundation Medicine, INC. | $91.77 | 2023 | |
| Genentech USA, INC. | $53.45 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joy Tang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.